AR058119A1 - Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui) - Google Patents
Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui)Info
- Publication number
- AR058119A1 AR058119A1 ARP060105610A ARP060105610A AR058119A1 AR 058119 A1 AR058119 A1 AR 058119A1 AR P060105610 A ARP060105610 A AR P060105610A AR P060105610 A ARP060105610 A AR P060105610A AR 058119 A1 AR058119 A1 AR 058119A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidin
- ethyl
- dihydro
- stui
- treatment
- Prior art date
Links
- 210000001635 urinary tract Anatomy 0.000 title 1
- -1 5-Acetyl-2-butoxy-3-pyridinyl Chemical group 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 2
- 229960002978 fesoterodine Drugs 0.000 abstract 2
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 abstract 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 abstract 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 abstract 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 229960005434 oxybutynin Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229960003510 propiverine Drugs 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229960003855 solifenacin Drugs 0.000 abstract 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960004045 tolterodine Drugs 0.000 abstract 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 abstract 1
- 229960001491 trospium Drugs 0.000 abstract 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 abstract 1
- 206010046494 urge incontinence Diseases 0.000 abstract 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso combinado de un inhibidor de PDE5 y un antagonista muscarínico en el tratamiento de síntomas del tracto urinario inferior (STUI), tales como urgencia, frecuencia, nocturia e incontinencia de urgencia y formulacion. Reivindicacion 2: Una formulacion de acuerdo con la reivindicacion 1, caracterizada porque el inhibidor de PDE5 se selecciona entre: sildenafil; tadalafil; vardenafil; 5-(5-acetil-2-butoxi-3-piridinil)-3-etil-2-(1-etil-3-azetildinil)-2,6-dihidro-7H-pirazol[4,3- d]pirimidin-7-ona; 5-(5-Acetil-2-propoxi-3-piridinil)-3-etil-2-(1-isopropil-3-azetildinil)-2,6-dihidro-7H-pirazol[4,3-d]pirimidin-7-ona; 4-[(3-cloro-4-metoxibencil)amino]-2-[(2S)-2-(hidroximetil)pirrolidin-1-il]-N-(pirimidin-2-ilmetil)pirimidin-5- carboxamida (TA-1790; 3-(1-metil-7-oxo-3-propil-6,7-dihidro-1H-pirazol[4,3-d]pirimidin-5-il)-N-[2-(1-metilpirrolidin-2-il)etil]-4-propoxibencenosulfonamida (DA 8159); y sales farmaccuticamente aceptables de los mismos. Reivindicacinn 5: Una formulacinn de acuerdo con cualquiera de las reivindicaciones anteriores,caracterizada porque el antagonista muscarenico se selecciona entre: atropina; fluvoxato; hioscina; oxibutinina; darifanacina; tolterodina; (+)-N,N-diisopropil-3-(2-hidroxi-5- hidroximetilfenil)-3- fenilpropilamina; propantelina, propiverina; trospium; solifenacina; fesoterodina; fesoterodina; y sales farmaccuticamente aceptables de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75262505P | 2005-12-20 | 2005-12-20 | |
US75772006P | 2006-01-09 | 2006-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058119A1 true AR058119A1 (es) | 2008-01-23 |
Family
ID=37946766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105610A AR058119A1 (es) | 2005-12-20 | 2006-12-19 | Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080318982A1 (es) |
EP (1) | EP1965863A2 (es) |
JP (1) | JP2007169278A (es) |
KR (1) | KR20080076961A (es) |
AR (1) | AR058119A1 (es) |
AU (1) | AU2006327882A1 (es) |
BR (1) | BRPI0620234A2 (es) |
CA (1) | CA2634019A1 (es) |
RU (1) | RU2008120332A (es) |
TW (1) | TW200733975A (es) |
WO (1) | WO2007072169A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807715B2 (en) * | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
WO2009019599A2 (en) * | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
WO2009056232A2 (en) * | 2007-10-30 | 2009-05-07 | Bayer Schering Pharma Aktiengesellschaft | Combination of pde5 inhibitors with muscarinic receptor antagonists |
EP2106792A1 (en) * | 2008-04-02 | 2009-10-07 | Pelvipharm | Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder |
ES2609061T3 (es) * | 2009-02-27 | 2017-04-18 | Krka, D.D., Novo Mesto | Procedimiento para formar unas formas farmacéuticas orales sólidas de solifenacina y sus sales farmacéuticamente aceptables |
EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2316432A1 (de) * | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
KR20110062943A (ko) * | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
EP2508175A1 (en) * | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
US20130236544A1 (en) * | 2012-03-08 | 2013-09-12 | Dr. Reddy's Laboratories Ltd. | Stable pharmaceutical compositions of fesoterodine |
BR112015021630A2 (pt) * | 2013-03-07 | 2017-07-18 | Amneal Pharmaceuticals Llc | estabilização de fármacos sensíveis à umidade |
US20140271847A1 (en) * | 2013-03-13 | 2014-09-18 | SatisPharma, LLC | Formulations and methods for rapid penile erections |
KR102239291B1 (ko) * | 2013-06-28 | 2021-04-14 | 한미약품 주식회사 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 |
US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
JP2015133989A (ja) * | 2015-04-28 | 2015-07-27 | 重泉 達志 | 健康食品 |
US10335453B2 (en) * | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8800207D0 (sv) * | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
SK285991B6 (sk) * | 1997-04-25 | 2008-01-07 | Pfizer Inc. | Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze |
AU3621097A (en) * | 1997-07-09 | 1999-02-08 | Wolf-Georg Forssmann | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
US6642274B1 (en) * | 1999-09-09 | 2003-11-04 | Gary W. Neal | Methods and compositions for preventing and treating prostate disorders |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
TR200200954T2 (tr) * | 1999-10-11 | 2002-09-23 | Pfizer Inc. | Fosfodiesteraz inhibitörleri olarak 5-(2-ikame edilmiş-5-heterosiklilsülfonilpirid-3-il)- dihidropirazolo[4,3- D]pirimidin-7-onlar. |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
-
2006
- 2006-12-19 TW TW095147592A patent/TW200733975A/zh unknown
- 2006-12-19 CA CA002634019A patent/CA2634019A1/en not_active Abandoned
- 2006-12-19 RU RU2008120332/15A patent/RU2008120332A/ru unknown
- 2006-12-19 US US12/093,358 patent/US20080318982A1/en not_active Abandoned
- 2006-12-19 AR ARP060105610A patent/AR058119A1/es unknown
- 2006-12-19 AU AU2006327882A patent/AU2006327882A1/en not_active Abandoned
- 2006-12-19 KR KR1020087014835A patent/KR20080076961A/ko not_active Application Discontinuation
- 2006-12-19 JP JP2006341662A patent/JP2007169278A/ja active Pending
- 2006-12-19 EP EP06821077A patent/EP1965863A2/en not_active Withdrawn
- 2006-12-19 BR BRPI0620234-9A patent/BRPI0620234A2/pt not_active IP Right Cessation
- 2006-12-19 WO PCT/IB2006/003683 patent/WO2007072169A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BRPI0620234A2 (pt) | 2011-11-01 |
JP2007169278A (ja) | 2007-07-05 |
RU2008120332A (ru) | 2010-01-27 |
CA2634019A1 (en) | 2007-06-28 |
EP1965863A2 (en) | 2008-09-10 |
WO2007072169A3 (en) | 2007-11-01 |
AU2006327882A1 (en) | 2007-06-28 |
WO2007072169A2 (en) | 2007-06-28 |
TW200733975A (en) | 2007-09-16 |
US20080318982A1 (en) | 2008-12-25 |
KR20080076961A (ko) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058119A1 (es) | Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui) | |
ES2575549T3 (es) | Comprimido de melatonina y métodos de preparación y uso | |
UY30327A1 (es) | Nuevos compuestos ii | |
DOP2010000191A (es) | Derivados bis-(sulfonilamino) | |
RU2008131792A (ru) | Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev | |
ECSP088589A (es) | Formas trihidrocloruro de un derivado de dihidropteridinona y procedimientos de preparación | |
PL1799633T3 (pl) | Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych | |
CL2019002238A1 (es) | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3 hidroxipirrolidina -1-carboxamida. (divisional solicitud 201802806) | |
PE20060292A1 (es) | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos | |
CR20140417A (es) | Inhibidores de cinasa de fosfoinositida 3 cristalina | |
SE0302487D0 (sv) | Novel compounds | |
HRP20120918T1 (hr) | Aminopirazolski spoj | |
RS53552B1 (en) | DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B | |
CO6251256A2 (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4il)1h-pirazol-1-il)-3-ciclopentilpropanitrilo | |
ECSP13012546A (es) | Formulación tópica para un inhibidor de jak | |
EA201270046A1 (ru) | Новые производные фенилимидазола в качестве ингибиторов фермента pde10a | |
CR8859A (es) | Derivados de piridina | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
UY31430A1 (es) | Derivados de piridina y pirazina -83 | |
HN2011000874A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
AR066206A1 (es) | Proceso para la sintesis de solifenacina | |
AR051792A1 (es) | Compuestos de aminobenzofenona triazol sustituidos | |
CR10492A (es) | Nuevos compuestos heterociclicos | |
CL2012000042A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |